Skip to main content
Top
Published in: Indian Journal of Pediatrics 10/2020

01-10-2020 | COVID-19 | Review Article

Vaccine Against Covid-19 Disease – Present Status of Development

Author: Ashok Kumar Dutta

Published in: Indian Journal of Pediatrics | Issue 10/2020

Login to get access

Abstract

The pandemic declaration of Covid-19 disease by World Health Organization (WHO) and subsequent widespread morbidities and mortalities in almost all countries of the world led to the research and development to find out a vaccine against SARS-CoV2 virus. Normally any new vaccine development takes 10–15 y time but the search for vaccine against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough in vaccine development by several research institutions and vaccine manufacturers. In pandemic situation, however, the entire process of vaccine development including clinical trials gets shortened and may be fast tracked to 15–18 mo time. It is expected that there shall be simultaneous marketing of several vaccines by the beginning of 2021. There are more than 164 candidate vaccines which are in the process of development and among them 24 vaccines are in advanced stages of development. This review aims at highlighting the present stages of development of vaccines and discussing the challenges that may be faced with these novel vaccines.
Literature
3.
go back to reference Douglas RG, Samant VB. The vaccine industry. In: Plotkins SA, Orenstein WA, Offit PA, editors. Vaccine. 6th ed. China: Saunders Elsevier; 2013. p. 33–43.CrossRef Douglas RG, Samant VB. The vaccine industry. In: Plotkins SA, Orenstein WA, Offit PA, editors. Vaccine. 6th ed. China: Saunders Elsevier; 2013. p. 33–43.CrossRef
4.
go back to reference Le Thanh T, Andreeadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305–6.CrossRef Le Thanh T, Andreeadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:305–6.CrossRef
6.
7.
go back to reference Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–54.CrossRef Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–54.CrossRef
Metadata
Title
Vaccine Against Covid-19 Disease – Present Status of Development
Author
Ashok Kumar Dutta
Publication date
01-10-2020
Publisher
Springer India
Keyword
COVID-19
Published in
Indian Journal of Pediatrics / Issue 10/2020
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-020-03475-w

Other articles of this Issue 10/2020

Indian Journal of Pediatrics 10/2020 Go to the issue